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Abstract  Chronic  diarrhoea  is  a  common  clinical  problem  in  gastroenterology  practice  and
often it  is  difﬁcult  to  diagnose  the  cause.  Villous  atrophy  is  not  speciﬁc  and  the  rarer  possibility
of drug-induced  enteritis  should  always  be  considered.  Olmesartan  has  recently  been  described
as a  cause  of  drug-induced  enteropathy  characterized  by  chronic  diarrhoea  and  varying  degrees
of duodenal  mucosa  atrophy  resembling  celiac  disease.
We describe  two  cases  of  sprue-like  enteropathy  in  patients  treated  with  olmesartan  for
arterial hypertension  several  years  before  the  onset  of  symptoms.  Patients  presented  severe
diarrhoea and  signiﬁcant  weight  loss,  and  both  had  histological  evidence  of  intestinal  villous
atrophy. The  clinical  signs  completely  resolved  after  drug  withdrawal.
Olmesartan-induced  enteropathy  is  a  new  clinical  entity  that  must  be  included  in  the  differ-
ential diagnosis  of  villous  atrophy  with  negative  celiac  serology.  The  clinical  and  histological
alterations  easily  and  completely  resolve  after  drug  discontinuation,  restoring  quality  of  life  to
patients and  avoiding  unnecessary  investigation.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.U.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
PALAVRAS-CHAVE
Atropﬁa/induzida
Enteropatia  Tipo  Celíaca  Induzida  Pelo  Olmesartanquimicamente;
Diarreia/induzida
Resumo  A  diarreia  crónica  é  um  problema  clínico  comum  na  prática  de  gastroenterologia
e, muitas  vezes,  o  diagnóstico  da  causa  é  difícil.  A  atroﬁa  das  vilosidades  intestinais  não  é
idade  de  enterite  induzida  por  fármacos  deve  ser  considerada.  O
te  descrito  como  uma  causa  de  enteropatia  induzida  por  fármacos
rónica  e  graus  variáveis  de  atroﬁa  da  mucosa  duodenal  semelhantequimicamente;
Olmesartan;
Mucosa  Intestinal
especíﬁca e  a  rara  possibil
olmesartan  foi  recentemen
caracterizada  por  diarreia  c
á doenc¸a  celíaca.∗ Corresponding author.
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Os  autores  descrevem  dois  casos  de  enteropatia  tipo  celíaca  em  doentes  com  história  de
hipertensão  arterial  medicada  com  olmesartan  vários  anos  antes  do  início  dos  sintomas.  Ambos
os doentes  apresentaram  diarreia  grave,  perda  ponderal  signiﬁcativa  e  evidência  histológica  de
atroﬁa vilositária.  Os  sinais  clínicos  resolveram  completamente  após  a  interrupc¸ão  do  fármaco.
A enteropatia  induzida  por  olmesartan  constitui  uma  nova  entidade  clínica  que  deve  ser
incluída no  diagnóstico  diferencial  de  atroﬁa  vilositária  seronegativa.  As  alterac¸ões  clínicas
e histológicas  resolvem  rápida  e  completamente  após  a  suspensão  do  fármaco  restaurando  a
qualidade de  vida  aos  doentes  e  evitando,  muitas  vezes,  investigac¸ões  invasivas  desnecessárias.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.
Este é  um  artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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2. Introduction
ntestinal  villous  atrophy  with  negative  celiac  serology  may
e  a  diagnostic  challenge.  Apart  from  celiac  disease,  a
ariable  degree  of  villous  atrophy  can  be  found  in  other
onditions  as  autoimmune  enteropathy,  common  variable
mmune  deﬁciency,  small  bowel  bacterial  overgrowth,  par-
sitic  infection  such  as  giardiasis,  intestinal  lymphoma,
uman  immunodeﬁciency  virus  infection-related  enteropa-
hy,  Whipple’s  disease,  and  tropical  sprue.  Villous  atrophy
an  also  occur  with  prolonged  use  of  some  medications.
An  association  between  olmesartan  and  enteropathy
evelopment,  which  is  histologically  indistinguishable  from
eliac  disease,  has  been  described  recently.1--4 Olmesartan-
nduced  enteropathy  can  cause  severe  chronic  diarrhoea
ith  substantial  weight  loss,  even  months  or  years  after
rug  initiation.  The  Food  and  Drug  Administration  issued
 statement  on  olmesartan  labelling  in  July  2013  after  a
ase  series  with  22  patients  was  reported  by  Mayo  Clinic.1
he  physiopathogenic  mechanism  of  olmesartan-induced
nteropathy  remains  unknown.  One  proposed  mechanism  is
elated  to  a  cell-mediated  immune  response  that  damages
he  small  intestinal  brush  border.1--5 Additionally,  a  predispo-
ition  in  patients  with  an  autoimmune  background  has  been
uggested.5,6
We  report  two  cases  of  severe  olmesartan-induced
nteropathy  and  discuss  the  natural  history  of  this  condition
. Clinical cases
.1.  Case  1
 60  year-old  Caucasian  male  with  arterial  hyperten-
ion,  treated  with  olmesartan  and  hydrochlorothiazide
20  +  12.5  mg/day)  for  the  last  4  years,  was  admitted  to  our
ospital  with  a  3-month  clinical  history  of  abdominal  pain,
iarrhoea  and  marked  weight  loss  (16%  body  weight).  He
eported  between  5  and  7  daily  episodes  of  watery  and  non-
loody  diarrhoea.  He  denied  any  other  symptoms  suggestive
f  local  or  systemic  infections,  recent  travel,  consumption
f  contaminated  food  or  water,  animal  contact,  or  changes
n  diet  or  medications  within  the  past  few  years.
Because  the  patient  was  dehydrated  and  had  tachycardia
ith  orthostatic  hypotension,  antihypertensive  drugs  were
iscontinued.  Abdominal  palpation  was  diffusely  painful  but
A
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phere  were  no  masses  or  organ  enlargement.  On  physical
xamination,  there  was  also  diffuse  skin  thickening  without
clerodactyly  or  telangiectasias.
Blood  tests  showed  hypokalaemia  (serum  potassium
.0  mmol/L;  N:  3.6--5.1),  hypophosphataemia  (phosphorus
.8  mg/dL,  N:  2.3--4.7),  and  hypoalbuminaemia  (albumin
.8  g/dL;  N:  3.4--4.8).  The  patient’s  leucocyte  count,  C-
eactive  protein  level,  and  liver  chemistries  were  all  normal.
he  remaining  initial  workup  including  immunoglobulin  lev-
ls,  serum  thyroid  stimulating  hormone,  stool  cultures,
lostridium  difﬁcile  toxin  assay,  stool  ova  and  parasites,
nd  stool  osmolality  and  electrolytes  was  unremark-
ble.  Conventional  serologic  tests  (tissue  transglutaminase,
ndomysial,  and  antigliadin  antibodies)  and  a  lack  of  clinical
esponse  to  a  gluten-free  diet  ruled  out  celiac  disease.
An  abdominal  CT  scan  showed  diffuse  small  bowel  wall
hickening  with  surrounding  mesenteric  adenopathy  (Fig.  1).
ancreatic  abnormalities  or  potential  malignancies  were
xcluded.  Colonoscopy  and  colonic  biopsies  were  normal,
nd  there  was  no  evidence  of  microscopic  colitis  or  inﬂam-
atory  bowel  disease.  Immunological  assays  were  positive
or  antinuclear  antibody  (titre,  1:1280)  and  Scl70  suggesting
 diagnosis  of  systemic  sclerosis  that  was  conﬁrmed  by  a  skin
iopsy.
During  hospitalization,  the  patient  had  progressive  clini-
al  and  analytical  improvements  and  was  discharged  with  an
ndication  for  clinical  and  analytical  reassessment.  A  month
ater,  diarrhoea  and  weight  loss  recurred.  Oral  ciproﬂoxacin
or  possible  small  bowel  bacterial  overgrowth  secondary
o  small  intestinal  dysmotility  of  systemic  sclerosis  was
nitiated,  but  he  did  not  show  any  clinical  improvement.
n  upper  gastrointestinal  endoscopy  was  performed  and
uodenal  biopsies  revealed  moderate  villous  blunting  and
ntraepithelial  lymphocyte  inﬁltration  (Fig.  2).  Because  of
linical  improvement  during  hospitalization  (without  antihy-
ertensive  drug)  and  intensiﬁcation  of  complaints  with  the
e-introduction  of  his  usual  medication,  olmesartan-induced
nteropathy  was  suspected.  The  drug  was  discontinued.
ithin  3  months,  the  patient  gained  weight  and  showed
esolution  of  analytical  changes.
.2.  Case  2 62  year-old  Caucasian  male  with  arterial  hypertension,
ho  was  administered  olmesartan  (20  mg/day)  for  5 years
reviously,  was  referred  for  a  gastroenterology  and  internal
Olmesartan-Induced  Enteropathy  103
F
(
3
s
1
l
a
(
p
dFigure  1  Computed  tomography  (CT)  of  abdomen  and  pelvis
showing  diffuse  bowel  wall  thickening.
medicine  consultation  because  of  chronic  watery  diarrhoea
(7--10  stools/day)  associated  with  pain  in  the  lower  abdomen
quadrant  and  a  25  kg  weight  loss  (19%  body  weight).  He
has  been  admitted  to  the  internal  medicine  department
several  times  in  the  previous  3  years  because  of  these
complaints.  He  denied  fever  and  any  other  relevant  epi-
demiological  context.  A  prior  colonoscopy  revealed  a  normal
mucosa  with  intraepithelial  lymphocyte  inﬁltration,  which
was  compatible  with  lymphocytic  colitis  detected  by  a
histopathological  examination.  Based  on  the  histological
ﬁndings,  he  underwent  treatment  with  multiple  courses  of
oral  steroids  (budesonide  9  mg/day)  and  antibiotics,  but  did
not  show  clinical  improvement.
m
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Figure  2  Small  intestinal  histological  examination  showing  sever
inﬁltrate in  lamina  propria  and  surface  intraepithelial  lymphocytosisigure  3  Upper  endoscopy  showing  duodenal  villous  atrophy.
Laboratory  evaluations  showed  normocytic  anaemia
11.9  g/dL;  N:  13--17),  hypoalbuminaemia  (20.9  g/L;  N:
.4--4.8),  and  severe  electrolyte  abnormalities  --  potas-
ium  2.3  mEq/L  (N:  3.6--5.1);  calcium  0.48  mmol/L  (N:
.15--1.35);  and  magnesium  0.77  mg/dL  (N:  1.6--2.6).  Sero-
ogy  for  celiac  disease  including  thyroid  hormone  levels
nd  autoantibodies,  stool  analysis  for  infectious  agents
Clostridium,  virology,  bacteriology,  mycobacteriology,  and
arasitology),  and  an  investigation  for  a  possible  neuroen-
ocrine  neoplasm  were  all  negative.Upper  endoscopy  revealed  patchy  erythema  of  the  antral
ucosa  and  villous  atrophy  of  the  duodenal  mucosa  (Fig.  3).
iopsies  showed  attenuated  villi  with  severe  inﬂammatory
spects  with  no  signs  of  granulomas,  microorganisms,  or
e  attenuated  villi  (A)  with  lymphoplasmmacytic  inﬂammatory
 (B)  (HE,  400×).
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Ethical disclosuresigure  4  Capsule  endoscopy  demonstrating  jejunoileitis  with
ucosal  ulceration.
alignancy.  Capsule  endoscopy  showed  jejunoileitis  with
ucosal  ulceration  (Fig.  4).  A  few  days  after  endoscopy,
he  patient  was  admitted  to  our  hospital  because  of  the
ersistence  of  symptoms  and  development  of  acute  renal
ailure.  In  this  context,  olmesartan  was  discontinued.  Within
8  h,  a  rapid  improvement  was  observed  with  resolution
f  the  diarrhoea.  After  discharge,  the  patient  restarted
lmesartan  and  immediate  recurrence  of  diarrhoea  was
oted.  Based  on  relapsing  symptoms,  simultaneous  with  long
eriods  of  drug  treatment,  olmesartan-induced  diarrhoea
as  suspected  and  the  drug  was  discontinued.  A  9-month
ollow-up,  he  showed  complete  resolution  of  diarrhoea  with
o  further  relapses,  despite  consuming  a  gluten-containing
iet.
. Discussion
rug-induced  sprue-like  enteropathy  must  be  considered  in
he  differential  diagnosis  of  patients  presenting  diarrhoea,
eight  loss,  and  unexplained  villous  atrophy  of  the  duodenal
ucosa.  In  2012,  Rubio-Tapia  et  al.1 reported  on  22  patients
ith  severe  olmesartan-induced  sprue-like  enteropathy.
he  most  frequent  symptoms  are  severe  chronic  diarrhoea
ith  substantial  weight  loss  (median,  18  kg),  but  nausea,
omiting,  abdominal  pain,  and  fatigue  can  be  present.
nteropathy  can  develop  months  to  years  after  olmesartan
nitiation,  although  case  reports  of  irbesartan  and  valsartan-
ssociated  enteropathy  have  also  been  described.2,6 In
he  majority  of  reported  cases,  patients  were  adminis-
ered  with  40  mg/day  olmesartan,  but  doses  of  10  mg/day
ight  be  sufﬁcient  to  cause  enteropathy.1 Laboratory
valuation  usually  shows  evidence  of  malabsorption  with
ormocytic  normochromic  anaemia,  hypoalbuminaemia,
nd  multiple  electrolyte  abnormalities.  Dehydration  and
cute  renal  failure  have  been  reported  as  the  main  causes
f  hospitalization,1--4 although  a  case  of  colonic  perforation
as  also  been  documented.7
As  in  celiac  disease,  olmesartan-induced  enteropathy
s  characterized  histologically  by  intestinal  villous  atrophy
P
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ith  mucosal  inﬂammation  and  lymphoid  aggregation.1,3
owever,  sprue-like  enteropathy  can  be  differentiated  from
eliac  disease  by  the  absence  of  tissue  transglutaminase  and
ndomysial  antibodies  and  the  lack  of  response  to  a  gluten-
ree  diet.  Rubio-Tapia  et  al.1 reported  pathologic  evidence
f  involvement  of  the  stomach  and  colon,  suggesting  that
his  disorder  may  affect  the  entire  gastrointestinal  tract,
s  demonstrated  here  in  the  second  case.  Discontinuation
f  olmesartan  led  to  clinical  improvement  and  histological
ecovery  in  all  patients  who  underwent  follow-up  biopsies
pproximately  18  months  later.1
At  present,  the  mechanisms  responsible  for  the  onset
f  enteritis  after  olmesartan  use  are  unknown.  The  long
elay  between  the  onset  of  olmesartan  therapy  and  the
evelopment  of  enteropathy  suggests  that  the  reaction  is
 localized,  delayed  hypersensitivity  response  that  is  cell-
ediated  and  results  in  damage  to  the  small  intestinal  brush
order.  In  addition,  angiotensin  receptor  blockers  have  been
uggested  to  have  inhibitory  effects  on  transforming  growth
actor,  which  is  responsible  for  gut  immune  homeostasis  and
aintaining  a  normal  balance  between  proinﬂammatory  and
nti-inﬂammatory  factors.1--5
Recent  ﬁndings  suggested  that  olmesartan-induced
nteropathy  had  an  immunological  basis  and  affected  pre-
isposed  individuals.  Rubio-Tapia  et  al.1 found  a  prevalence
f  HLA-DQ2  in  68%  of  patients  with  olmesartan-associated
nteropathy,  signiﬁcantly  higher  than  the  expected  for
he  general  population  (25--30%).  These  ﬁndings  were
einforced  by  Scialom  et  al.5 In  their  study,  extraintesti-
al  autoimmune  diseases  were  found  in  three  of  seven
atients  who  developed  olmesartan-induced  enteropathy,
nd  immunosuppressive  drugs  induced  remission  in  all
atients  before  olmesartan  discontinuation.  Together  these
ata  support  caution  when  using  olmesartan  in  patients
ith  an  autoimmune  background.  In  the  ﬁrst  patient
resented  here,  systemic  sclerosis  may  have  been  a  predis-
osing  factor  for  the  development  of  olmesartan-induced
nteropathy.
Discontinuation  of  olmesartan  should  be  considered  in
ases  where  another  aetiology  has  not  been  identiﬁed.
hen  symptoms  disappear  and  sprue-like  enteropathy  is
onﬁrmed  by  biopsy,  treatment  with  olmesartan  should  not
e  restarted  because  of  the  life-threatening  nature  of  the
yndrome.
. Conclusion
hese  cases  highlight  the  importance  for  clinicians  to  main-
ain  a  high  index  of  suspicion  for  olmesartan  as  a  cause  of
pruelike  enteropathy,  since  this  entity  may  not  be  so  rare.
he  early  recognition  of  such  relationship  is  important  due
o  widespread  use  of  this  drug,  to  avoid  delay  in  establish-
ng  a  correct  diagnosis  and  to  avoid  frustrating,  unnecessary
nd  often  expensive  investigation.rotection  of  human  and  animal  subjects.  The  authors
eclare  that  no  experiments  were  performed  on  humans  or
nimals  for  this  study.
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